Casopitant is a potent and selective neurokinin-1 receptor antagonist formerly under development for a number of indications, including the treatment of chemotherapy-induced nausea and vomiting. This study was an open-label, randomized, multi-center, two-period crossover casopitant-cyclophosphamide interaction study. Subjects were cancer patients receiving cyclophosphamide based chemotherapy. The objectives of the study were to assess the effect of 3-day, repeat-dose, 150 mg oral casopitant on the pharmacokinetics (PK), safety, tolerability, and pharmacodynamics (white blood cell count) of single-dose IV cyclophosphamide. PK data from 14 evaluable subjects showed the geometric least-squares mean ratios (90% CI) for cyclophosphamide and the metabolite 4-hydroxycyclophosphamide AUC (with:without casopitant) were 1.03 (0.975, 1.09) and 0.948 (0.835, 1.08), respectively. Administration of casopitant was well tolerated and did not impact the safety profile of the treatment regimen. Casopitant did not affect the expected bone marrow toxicity of cyclophosphamide. Co-administration of 150 mg oral casopitant with single-dose IV cyclophosphamide did not appear to result in a clinically relevant change in cyclophosphamide or 4-hydroxycyclophosphamide exposure or safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cpdd.57 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Homology modeling, virtual screening, molecular docking, and ADME approaches to identify a potent agent targeting NK2R protein.
Biotechnol Appl Biochem
February 2024
Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Neurokinin/tachykinin receptors are classified as the G-protein coupled receptor superfamily. The neurokinin 2 receptor (NK2R) is widely expressed in different tissues. NK2R is associated with a range of biological events, such as inflammation, smooth muscle contraction, intestinal motor functions, and asthma.
View Article and Find Full Text PDFA pharmacokinetic, pharmacodynamic, and safety study of intravenous cyclophosphamide with an oral casopitant antiemetic regimen in cancer patients.
Clin Pharmacol Drug Dev
March 2014
GlaxoSmithKline, Research Triangle Park, North Carolina.
Casopitant is a potent and selective neurokinin-1 receptor antagonist formerly under development for a number of indications, including the treatment of chemotherapy-induced nausea and vomiting. This study was an open-label, randomized, multi-center, two-period crossover casopitant-cyclophosphamide interaction study. Subjects were cancer patients receiving cyclophosphamide based chemotherapy.
View Article and Find Full Text PDFA pharmacokinetic PET study of NK₁ receptor occupancy.
Eur J Nucl Med Mol Imaging
February 2012
GlaxoSmithKline, Clinical Pharmacology Modeling & Simulation, Stockley Park, UK.
Purpose: There is growing recognition of the importance of integrating drug occupancy data acquired by positron emission tomography (PET) with the plasma pharmacokinetics of the drug, in order to establish proper dose selection in subsequent clinical trials. Here we present a study in human subjects of the occupancy of NK(1) receptors achieved following different doses of casopitant, a selective NK(1) antagonist.
Methods: Two PET scans were carried out in each of eight human subjects, with the PET radioligand [(11)C]GR205171, a high-affinity and selective NK(1) receptor antagonist.
NT-proBNP as a biomarker for the assessment of a potential cardiovascular drug-induced liability in beagle dogs.
Cell Biol Toxicol
December 2011
Safety Assessment Department, GlaxoSmithKline Research Centre, Verona, Italy.
The amino-terminal pro-brain natriuretic peptide (NT-proBNP) is released into the plasma predominantly from ventricular cardiomyocytes, particularly in patients with chronic cardiac diseases, although small amounts are detectable in the plasma of healthy subjects. While NT-proBNP has been widely exploited in human medicine, limited literature is available related to its characterization in veterinary medicine (e.g.
View Article and Find Full Text PDFSingle-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.
Support Care Cancer
July 2012
Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington, MA 01805, USA.
Purpose: The primary objective was to determine if a single dose of casopitant 90 mg added to ondansetron and dexamethasone would improve the control of chemotherapy-induced nausea and vomiting (CINV) over 0-120 h following initiation of oxaliplatin-based moderately emetic chemotherapy (MEC) compared to ondansetron and dexamethasone alone.
Methods: Patients with colorectal cancer received either casopitant or placebo intravenously (IV) added to ondansetron 8 mg bid oral on study days 1 to 3 and one dose of dexamethasone 8 mg IV given prior to starting the oxaliplatin on day 1. The primary endpoint was the percentage of subjects achieving complete response (CR; no vomiting/retching or use of rescue medication) during 120 h after initiation of chemotherapy in cycle 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!